Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Omiatek, F. Leifer, V. Malinin, J. Ong, T. Henn, Z. Li, R. Chapman, D. Salvail, C. Laurent, W. Perkins (Monmouth Junction, United States Of America; Sherbrooke, Canada). Incorporation into lipid nanoparticles extends the duration of activity of treprostinil in an acute hypoxia rat model of pulmonary arterial hypertension. Eur Respir J 2014; 44: Suppl. 58, 2357

Member's Comments

No comment yet.

Related content which might interest you: Prolonged activity of inhaled treprostinil prodrug nanoparticles in a rat model of pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 The evolution of effort tolerance and body composition in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Chronic thromboembolic vasculopathy with exercise induced PH but normal resting haemodynamics Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Sildenafil improves heart rate variability, pulmonary hemodynamics and functional status in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Female pulmonary arterial hypertension is associated with decreased microRNA96 expression Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Cerebral tissue oxygenation in arterial and thromboembolic pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 LATE-BREAKING ABSTRACT: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 Characteristics of patients with pulmonary hypertension in end stage renal disease Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Unique characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease compared to the rest of pulmonary arterial hypertension subgroups Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Beta-blocker therapy nor hyperoxic breathing lowers ventilatory drive in pulmonary arterial hypertension patients Source: International Congress 2014 – Pulmonary hypertension: right ventricular function, exercise and gas exchange Year: 2014 Impact of sepsis in respiratory mechanics of pulmonary arterial hypertension rat model. Preliminary results Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 The flavonoid quercetin reverses monocrotaline-induced pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Molecular study of genetic modifiers in patients with pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Inflammasome ASC-knock out attenuates the development of pulmonary hypertension caused by chronic alveolar hypoxia Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 miR-126; link between angiogenesis and exercise intolerance in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Muscle function and physical activity in patients with idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Pulmonary hypertension correction in patients with chronic obstructive pulmonary disease and essential hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Smad1 deficiency and female gender contribute to the development of pulmonary hypertension Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Nebivolol and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014